Clinical Trials Logo

Filter by:
NCT ID: NCT02519452 Completed - Multiple Myeloma Clinical Trials

A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Start date: October 22, 2015
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the pharmacokinetics and safety from the mixture of daratumumab and rHuPH20 prepared immediately before administration via Subcutaneous (SC) delivery (Part 1) and CF (co-formulated daratumumab and rHuPH20 preparation) administration via SC delivery of daratumumab (Part 2) and to evaluate the safety of Dara-CF 1800 milligram (mg) SC delivery without pre-dose and post-dose corticosteroids (Part 3).

NCT ID: NCT02518737 Completed - Bone Remodeling Clinical Trials

Examination of the Postprandial Bone Remodeling in Persons With Reduced GIP-Receptor Activity

Start date: September 2015
Phase: N/A
Study type: Observational

The bone tissue of the human adult body is in a constant process of break-down (resorption) and rebuilding (formation), a process called bone remodeling. The extent to which bone remodeling happens varies during the day, especially a decrease in the bone resorption is observed after eating. The overall purpose of this study is to examine the possible role of the hormone Glucose-dependent Insulinotropic Polypeptide (GIP) in Bone Remodeling. GIP is released from cells in the gut after eating, and previous studies have shown an effect of GIP on bone tissue. In addition, it has been observed that the risk of bone fracture is 60% higher in women with a mutation in the GIP receptor, when compared to women with a normal functioning GIP receptor. In the present study humans with a mutation in their GIP receptor is compared to humans with a normal functioning GIP receptor. The study population will be examined during a meal stimulation test, where blood will be sampled regularly. The blood samples will be examined for markers of bone resorption among other markers of bone remodeling, GIP and other gut hormones. The hypothesis for the present study is that GIP secreted after meal ingestion inhibits bone resorption. Thus it is expected that the decrease in resorption is less pronounced in the humans carrying the GIP-receptor mutation, compared to humans with a normal functioning GIP receptor.

NCT ID: NCT02518477 Completed - Breast Neoplasms Clinical Trials

Preventive Intervention Against Lymphedema After Breast Cancer Surgery

LYCA
Start date: September 2015
Phase: N/A
Study type: Interventional

This study will examine whether lymphedema after breast cancer surgery can be reduced. In a randomised controlled design the aim is to investigate whether an early intervention with progressive resistance training and close monitoring of arm swelling can reduce the incidence of lymphedema after breast cancer surgery.

NCT ID: NCT02516813 Completed - Clinical trials for Advanced Solid Tumors

Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy

Start date: September 15, 2015
Phase: Phase 1
Study type: Interventional

MSC2490484A or M3814 is an investigational drug that is being evaluated for the treatment of subjects with locally advanced tumors. The main purposes of this study are to determine the safety, the tolerability and the efficacy of MSC2490484A in combination with radiotherapy and in combination with chemoradiotherapy (Radiotherapy + cisplatin).

NCT ID: NCT02515331 Completed - Clinical trials for Patients, Resistant Hypertension

Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients

Start date: November 4, 2015
Phase: Phase 2
Study type: Interventional

The purpose of the present study was to determine whether LHW090 displays the clinical safety and efficacy profile to support further development in patients with resistant hypertension.

NCT ID: NCT02514473 Completed - Cystic Fibrosis Clinical Trials

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

Start date: July 2015
Phase: Phase 3
Study type: Interventional

To evaluate the efficacy and safety of lumacaftor in combination with ivacaftor in subjects aged 6 Through 11 years with cystic fibrosis (CF), homozygous for the F508del CF transmembrane conductance regulator (CFTR) mutation

NCT ID: NCT02510742 Completed - Chronic Migraine Clinical Trials

Physiological Changes With SPG Stimulation in Migraine Patients

Start date: July 2015
Phase: N/A
Study type: Interventional

Hypothesis: Stimulation of the SPG at low frequencies (20 Hz)is believed to cause a physiological parasympathetic upregulation which increases VMCA, concentration and cephalic vessel diameter.

NCT ID: NCT02510729 Completed - Clinical trials for Chronic Cluster Headache

SPG Neurostimulation in Cluster Patients

Start date: July 2015
Phase: N/A
Study type: Interventional

We hypothesized that LF stimulation of the SPG would increase parasympathetic outflow, activate sensory afferents and provoke a cluster-like attack.

NCT ID: NCT02508844 Completed - Obesity Clinical Trials

Effect of Probiotics (Vivomixx®) on Weight, Microbiota and Glucose Tolerance in Obese Pregnant Women and Their Newborn

POP
Start date: April 2015
Phase: Phase 4
Study type: Interventional

The purpose of the study is to investigate if the probiotics Vivomixx® can affect gestational weight gain, microbiota and pregnancy complications in pregnant obese women and birth weight body composition of their infants.

NCT ID: NCT02507687 Completed - Ocular Hypertension Clinical Trials

Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension

Start date: August 27, 2015
Phase: Phase 3
Study type: Interventional

This study will evaluate the intraocular pressure (IOP)-lowering effect and safety of bimatoprost SR compared with selective laser trabeculoplasty in patients with open-angle glaucoma or ocular hypertension who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy (e.g., due to intolerance or nonadherence).